Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

The Food and Drug Administration (FDA) has granted traditional approval to Calquence (acalabrutinib) with bendamustine and Rituxan (rituximab) for adults with previously untreated mantle cell lymphoma ...

“With today’s approval, Calquence provides a critical new treatment option to mantle cell lymphoma patients in the US, with Calquence proven to deliver nearly one and a half years of ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...

The Bruton tyrosine kinase inhibitor was approved in combination with bendamustine and rituximab in previously untreated mantle cell lymphoma ... translocation t(11;14)(q13;q32) and/or ...

FDA Approves New Drug Combination for Mantle Cell LymphomaThe FDA has approved a new pill to treat adults with a type of blood cancer called mantle cell lymphoma (MCL).

Investing.com -- AstraZeneca (LON:AZN) in a stock exchange filing on Friday said that the FDA approved its drug Calquence (acalabrutinib) to treat previously untreated mantle cell lymphoma (MCL ...